Yungan Tao

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ravindra Uppaluri, Robert I. Haddad, Yungan Tao et al. · New England Journal of Medicine · 2025 · 153 citations

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Jean Bourhis, Anne Aupérin, Christian Borel et al. · Journal of Clinical Oncology · 2025 · 36 citations

Surgical Oncology, Neoadjuvant Therapy, Lba2 Background +21

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

Yungan Tao, Anne Aupérin, Xu Sun et al. · Journal of Clinical Oncology · 2018 · 19 citations

Cohort 1, High Dose Cisplatin, Pharmacotherapy +22

Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.

Jean Bourhis, Xu Sun, Christian Sire et al. · Journal of Clinical Oncology · 2016 · 14 citations

Radiation Medicine, Oncology, Minimization Factors +16

High incidence of cetuximab-related infusion reactions in head and neck patients

Virginia Palomar Coloma, Pamela Eguiguren Bravo, Naima Lezghed et al. · ESMO Open · 2018 · 12 citations · Full text